We anticipate a high level of demand for our products, as they will allow labs to save money, time and
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new patent application for simplified sample
Murrieta Genomics has partnered with Life Science Nation (LSN) and the RESI (Redefining Early Stage Investments) Conference to offer startup
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new patent application for simplified sample
Murrieta Genomics has partnered with Life Science Nation (LSN) and the RESI (Redefining Early Stage Investments) Conference to offer startup
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new patent application for simplified sample
Murrieta Genomics has partnered with Life Science Nation (LSN) and the RESI (Redefining Early Stage Investments) Conference to offer startup
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new patent application for simplified sample
Murrieta Genomics has partnered with Life Science Nation (LSN) and the RESI (Redefining Early Stage Investments) Conference to offer startup
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new patent application for simplified sample
Murrieta Genomics has partnered with Life Science Nation (LSN) and the RESI (Redefining Early Stage Investments) Conference to offer startup
The RuleOut team has created a novel approach that can exponentially increase COVID-19 testing capacity.
Life Science Nation provides an incredibly important service to early stage life science companies by connecting them with products, services
John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with
Murrieta Genomics start-up TX Genetic Research was recently awarded second place in a national competition held by Golden Helix,